Critical Survey: Iterum Therapeutics (NASDAQ:ITRM) & Xeris Biopharma (NASDAQ:XERS)

Iterum Therapeutics (NASDAQ:ITRM) and Xeris Biopharma (NASDAQ:XERS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Iterum Therapeutics and Xeris Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Xeris Biopharma	-5.12%	338.21%	3.50%

Earnings and Valuation

This table compares Iterum Therapeutics and Xeris Biopharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390,000.00	4.10	-$24.77 million	($0.75)	-0.04
Xeris Biopharma	$291.85 million	6.84	$550,000.00	($0.11)	-99.59

Xeris Biopharma has higher revenue and earnings than Iterum Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Iterum Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Institutional & Insider Ownership

9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 42.7% of Xeris Biopharma shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by company insiders. Comparatively, 4.3% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Iterum Therapeutics and Xeris Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1	2	0	0	1.67
Xeris Biopharma	1	2	4	0	2.43

Xeris Biopharma has a consensus price target of $13.20, suggesting a potential upside of 20.49%. Given Xeris Biopharma’s stronger consensus rating and higher probable upside, analysts clearly believe Xeris Biopharma is more favorable than Iterum Therapeutics.

Summary

Xeris Biopharma beats Iterum Therapeutics on 11 of the 14 factors compared between the two stocks.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.